Followers | 9 |
Posts | 1278 |
Boards Moderated | 1 |
Alias Born | 09/09/2000 |
Thursday, August 01, 2002 9:08:53 AM
Give him a call 602-808-9771 then come back and post on what you think is going to happen.
Wise
Wise Investments
http://www.wise-investments.net
Wise
Recent JANX News
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/08/2024 09:47:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/08/2024 09:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:11:29 PM
- Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights • Business Wire • 03/08/2024 09:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/29/2024 10:30:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 10:11:11 PM
- Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants • Business Wire • 02/29/2024 06:22:00 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 02/29/2024 02:55:17 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 10:15:06 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/28/2024 02:50:39 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 10:23:20 PM
- Janux Therapeutics Announces Proposed Public Offering of Common Stock • Business Wire • 02/27/2024 10:00:00 PM
- Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors • Business Wire • 02/26/2024 09:05:00 PM
- Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 • Business Wire • 02/20/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/09/2024 09:31:05 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/01/2024 09:15:27 PM
- Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer • Business Wire • 01/08/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:54:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:53:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:50:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:49:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:47:56 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:45:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 09:19:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:07:54 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM